Key Highlights
- Third quarter Revenue was USD 47.56 million against a USD 41.88 million estimate, and EPS was USD -1.37.
- Net product revenue from MYQORZO was USD 44.5 million, and collaboration revenues were USD 3.05 million in the quarter.
- Cash and investments totaled USD 1.6 billion at September 30, including USD 203.43 million of cash and cash equivalents.
- The FDA assigned a PDUFA date of November 14, 2026 to the MAPLE-HCM supplemental application for MYQORZO.
The nearest dated event in Cytokinetics, Incorporated (NASDAQ:CYTK) disclosures is a regulatory one: the FDA assigned a standard review and a PDUFA date of November 14, 2026 to a supplemental new drug application that would add MAPLE-HCM results to the MYQORZO label. The company also plans to submit a supplemental application for symptomatic nonobstructive hypertrophic cardiomyopathy in the fourth quarter of 2026. Third quarter revenue was USD 47.56 million against an estimate of USD 41.88 million, and the net loss was USD 1.37 per share against an estimate of USD 1.43.
Regulatory Timeline and Commercial Footprint
MYQORZO (aficamten) was approved by the FDA in December 2025 and became available to patients around January 27, 2026. The European Commission approved it in February 2026, the United Kingdom granted a Marketing authorization in July, and Health Canada issued a Notice of Compliance in October. The company began commercial activity in Germany in the second quarter, and a UK launch is planned for later this year. Sanofi holds commercial rights in China and Taiwan.
ACACIA-HCM, the Phase 3 trial in nonobstructive disease, met both dual primary endpoints in results presented in August 2026. The company also completed the first cohort of CEDAR-HCM, a pediatric trial, in the third quarter.
The Quarter in Detail
Total revenues were USD 47.56 million against USD 1.94 million a year earlier, composed of USD 44.51 million of net product revenue and USD 3.05 million of collaboration revenues. Nine-month total revenues were USD 95.54 million against USD 70.28 million, which included license and milestone revenues of USD 11.93 million against USD 64.35 million.
Selling, general and administrative expense was USD 113.14 million against USD 69.46 million, and Research and Development expense was USD 99.29 million against USD 97.30 million. The operating loss was USD 167.09 million against USD 166.76 million. Non-cash interest expense on liabilities tied to revenue participation agreements was USD 23.64 million against USD 14.97 million. The net loss was USD 190.07 million against USD 306.18 million, a prior-year figure that included USD 121.25 million of Debt conversion expense, and the loss per share was USD 1.37 against USD 2.55.
Operations Detail: Cash, Debt and Offerings
Cash and cash equivalents were USD 203.43 million, short-term investments were USD 926.59 million and Long-Term Investments were USD 453.63 million. In May, the company closed a public offering of 11,338,028 shares at USD 71.00 per share, with net proceeds of about USD 760.1 million. Convertible notes outstanding comprised USD 140.5 million of 2027 notes, classified as current, and USD 750.0 million of 2031 notes.
Management said existing cash and investments are sufficient to fund requirements for at least twelve months. The company also disclosed a declaratory judgment complaint it filed in August against Bristol-Myers Squibb and its MyoKardia Subsidiary concerning a Patent that recites aficamten.
Next Reporting Checkpoints
Revenue of USD 47.56 million sits alongside net product revenue of USD 44.5 million, a net loss of USD 190.07 million and cash and investments of USD 1.6 billion. The net loss per share of USD 1.37 compares with an estimate of USD 1.43.
Management named several dated items. The MAPLE-HCM supplemental application has a PDUFA date of November 14, 2026. A supplemental application for nonobstructive disease is planned for the fourth quarter of 2026, and the company said the FDA may or may not accept or approve it. The UK launch is planned for later this year, and commercial rollout in additional major European countries follows the German start.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...